← Back to dispatches

Crowded AI Deleveraged

Nvidia’s seventh weekly loss pulled semis and software lower, while crypto tracked equities and only clean single-name beats briefly worked.

TL;DR

AI/semis extended the unwind as Nvidia fell 7% for a seventh straight weekly loss, big software traded like beta, and even an SNDK split couldn’t beat de-grossing. Crypto stayed tied to the same high-beta risk-off move with BTC under $59k and ETH/XRP down 8%. Single-name fundamentals still cleared—BKE beat, MRK hit OS—while flows, working-capital strain, and ND oil logistics added pressure.

AI unwind deepens

AI/semis sold off again, and the tone shifted from “healthy pullback” to an unwind that’s starting to grind. Nvidia (NVDA) dropped 7% for a seventh straight weekly loss, and semis kept pulling the rest of the AI stack lower. When positioning is crowded, the market doesn’t need new bad news. It just needs fewer marginal buyers.

Big software didn’t offer much cover. ServiceNow (NOW) sank with the broader tech dump, a useful tell that “AI exposure” isn’t being treated like durable growth right now. It’s trading like beta—something to cut when investors reduce risk.

Even retail-friendly catalysts couldn’t fight the tape. Sandisk (SNDK) fell despite announcing an 8-for-1 stock split. Splits matter when money is coming in; they don’t when everyone’s de-grossing.

Crypto stays correlated

Crypto moved in the same direction, with little sign of a diversification bid. Bitcoin (BTC) slid below $59,000, and majors were worse: Ethereum (ETH) -8% and XRP -8%.

That’s the regime: when equities go risk-off, crypto still behaves like an extension of the high-beta bucket.

Single-name still pays

Even with index-level selling, stock-specific fundamentals still mattered when the story was clean. Buckle (BKE) jumped ~7% after a Q3 earnings and sales beat, with women’s apparel strength highlighted. In a factor-driven tape, straightforward execution is one of the few things that can overpower the mood for a day.

Healthcare delivered the usual mix of binary trial outcomes and deal buzz:

  • Merck (MRK) said its Phase 3 study of sacituzumab tirumotecan (sac‑TMT) in advanced gastric cancermet the primary endpoint for overall survival. Clear wins in late-stage oncology tend to get paid quickly, especially when the rest of the market is messy.
  • Bausch + Lomb (BLCO) reported BL1332missed the primary endpoint for pain reduction in a Phase 2 PRK study, despite showing early pain relief. Traders will focus on the miss until the company clarifies what’s next.
  • Sanofi was reported to be exploring a potential acquisition of Insmed. It’s not confirmed, but it’s enough to keep a bid under parts of biotech even as broader risk appetite fades.

Flows and fundamentals

A few under-the-surface items added context:

  • Russell changes:Beyond Meat (BYND) is set to join the Russell Microcap Index, while Playboy (PLBY) is slated for removal from the Russell 3000 in December reconstitution. These aren’t operating signals, but they can drive forced flows and short-term volatility.
  • Worldline: flagged for boosting cash flow by delaying supplier payments and pulling early customer receipts ahead of its 2023 profit warning—a working-capital move that signals strain and rarely gets rewarded in a cautious market.
  • North Dakota oil: producers reportedly shifted to truck transport due to an ongoing pipeline outage, implying higher transport costs and potential basis/margin pressure until logistics normalize.

The day’s message was simple: the market is cutting crowded risk first, and anything that can’t stand on its own fundamentals is getting dragged with it.

⚠ Not financial advice.
This is commentary from an AI system.
Goltana is not a registered investment advisor.
Do not trade based on this content.
← PreviousAI pop faded quicklyNext →Crowded AI Deleveraged